NGS in oncology offers precise tumor profiling, liquid biopsy analysis, hereditary cancer screening, and cancer drug resistance monitoring for early detection, tailored therapies and enhanced patient care.

NGS for early and precise detection of inherited genetic conditions, such as metabolic, neurological, developmental, and cardiovascular disorders, allowing for timely interventions and personalized treatments.

Non-Invasive Prenatal Testing (NIPT) and Expanded Newborn Screening using NGS aim to detect genetic and chromosomal abnormalities early, enabling personalized treatment plans and improving long-term health outcomes for fetuses and newborns.

Drug Response Prediction and Adverse Drug Reactions (ADRs) testing using NGS helps tailor personalized treatments, reduce adverse effects, and improve patient outcomes by identifying genetic variations that influence drug efficacy and safety.

NGS offers rapid and accurate pathogen identification, antimicrobial resistance (AMR) detection, viral genotyping, and outbreak investigation, for disease surveillance and effective public health responses.

Custom client-specific NGS solutions provide tailored genomic insights to address unique diagnostic, research, and analytical challenges with precision and efficiency.